Results 161 to 170 of about 3,443,207 (253)

Comprehensive Review on PARP Inhibitors in Ovarian Cancer: A Breakthrough in Diagnostic and Therapeutic Approaches [PDF]

, 2023
Marcus Vetter, Viola Heinzelmann
openalex   +1 more source

Supplementary Data from ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

, 2023
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W.G. Wijnhoven, Adina Hughes, Joe Gerrard, Gemma N. Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A. Young, Mark J. O’Connor, Alan Pak Tao Lau   +11 more
openalex   +1 more source

Filling in the gaps in PARP inhibitor-induced synthetic lethality [PDF]

, 2021
Mariana Paes Dias, Jos Jonkers
openalex   +1 more source

Supplementary Table S4 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone, Jens‐Michael Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Stefan Prechtl, Simon J. Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Vera Pütter, Marion Hitchcock, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg   +18 more
openalex   +1 more source

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

, 2022
Tanja Pejović, Katherine Fitch, Gordon B. Mills   +2 more
openalex   +2 more sources

Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lewis GJ, Jewell RC, Krishnatry AS, Taskar KS.   +3 more
europepmc   +1 more source

Figure S2 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

, 2023
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop‐Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore‐Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchiò, Simona Corso, Silvia Giordano   +32 more
openalex   +1 more source

The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review. [PDF]

Front Oncol
Panjarwanto DA, Nabila P, Octavia L, Indrawan IWA, Utomo RP, Permana AY, Kaspan, Adnyana IGHE, Javier RM, Akbar MZH.   +9 more
europepmc   +1 more source

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source

RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]

Sci Rep
Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.   +4 more
europepmc   +1 more source